Skip to main content

Table 3 Cardiovascular benefits of SGLT2 inhibitors

From: Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management

Agents MACEs (HR) CV death (HR) HF (HR) Renal outcome (HR)
Empagliflozin [56] 0.86 0.62 0.65 0.5
Canagliflozin [57] 0.86 0.87 0.67 0.6
Dapagliflozin [58] 0.93 0.98 0.73 0.76
Ertugliflozin [59] 0.97 0.92 0.7 0.81
Tofogliflozin [60]
Luseogliflozin [61]
Ipragliflozin [61]
  1. – limited data, MACE major adverse cardiac event, HR hazard ratio, CV cardiovascular, HF heart failure